SI-BONE Names Six Growth Drivers But Holds Back 2027 Outlook Until Late February
The CFO was pressed on a Street 2027 growth estimate of about 15.5% and said guidance will come with fourth-quarter results.
SI-BONE, which makes titanium implants for sacroiliac joint dysfunction and other compromised-bone procedures, would not say whether Wall Street's roughly 15.5% 2027 revenue growth estimate is too low. On the company's third-quarter earnings call Monday, CFO Anshul Maheshwari listed six tailwinds and put off any 2027 outlook until late February.
Six tailwinds, no number
An analyst said the Street sits at about 15.5% top-line growth for next year and asked whether that looks low, given the company's press release language about the strongest foundation for growth acceleration in its history. Maheshwari said the company does not make that comment "lightly."
He named six drivers: interventional spine call-point expansion, proposed site-of-care coverage changes from Medicare, the Smith and Nephew trauma collaboration, new DRGs (hospital payment categories) for granite, the Onyx rollout through 2028, and a potential Onyx new-technology add-on payment at the end of 2027.
Still, he said management wants "a few more months behind us" and will discuss guidance when it reports fourth-quarter results in late February. "We're going to consistently be thoughtful and prudent in our approach," he said.
A fourth quarter above 20%
The 2026 outlook was reaffirmed at $231 million to $233 million in revenue. CEO Laura Francis said the midpoint implies fourth-quarter growth above 20%.
Third-quarter revenue rose 14.5% to $55.7 million, with US revenue up 13.9% to $52.8 million on 19.5% procedure volume growth. Adjusted EBITDA rose 32.4% to $3 million, and the net loss narrowed to $3.6 million, or $0.08 a share, from $4.6 million.
Maheshwari said operating expenses are now expected to grow 10.5% this year, down from a prior expectation of 12%. Cash stood at $146.3 million.
Onyx and the reimbursement catalysts
Onyx, a new implant aimed at screw loosening at the ends of spinal fusion constructs, received FDA clearance in September and began an alpha launch in October. Francis said early demand is tracking ahead of granite's, with full launch expected in January.
New granite DRGs took effect October 1 and could raise the average hospital payment by up to $50,000 per qualifying procedure, she said. Francis said the final Medicare ruling on proposed SI joint payment increases is expected in the coming days; if finalized, the changes take effect January 1, 2027.
Maheshwari also said 2027 will bring modest gross margin pressure from depreciation on added Onyx surgical sets. The company's market value was $951 million after Monday's report.
The Medicare payment ruling is due within days, and the 2027 outlook follows in late February with fourth-quarter results.
Sources
- SI-BONE (SIBN) Shares Just Moved, So What Is Going On? — Yahoo Finance
- SI-BONE GAAP EPS of -$0.08 beats by $0.05, revenue of $55.7M beats by $0.39M (SIBN:NASDAQ) | Seeking Alpha — seekingalpha.com
- Si-Bone Inc. : Articles :: Law360 — law360.com
- SI-BONE, Inc. Reports Financial Results for the Third — globenewswire.com